Circulating cathepsin K as a potential novel biomarker of coronary artery disease

Atherosclerosis

Volumn 228, Issue 1, 2013, Pages 211-216

  Cheng, Xian Wu ^a,c,d   Kikuchi, Ryosuke ^a   Ishii, Hideki ^a   Yoshikawa, Daiji ^a   Hu, Lina ^a   Takahashi, Ryotaro ^b   Shibata, Rei ^a   Ikeda, Nobuo ^b   Kuzuya, Masafumi ^a   Okumura, Kenji ^a   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Chunichi Hospital   (Japan)

^c YANBIAN UNIVERSITY   (China)

^d Kyung Hee University College of Medicine   (South Korea)

Author keywords

Atherosclerotic plaque; Biomarker; Cathepsin K; Coronary artery disease; Extracellular matrix protein degradation

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; INSULIN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTICLE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; INTRAVASCULAR ULTRASOUND; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

AGED; BIOLOGICAL MARKERS; CATHEPSIN K; COLLAGEN TYPE I; CORONARY ARTERY DISEASE; EXTRACELLULAR MATRIX; FEMALE; HUMANS; LIPIDS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDES; PLAQUE, ATHEROSCLEROTIC; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84876800440     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.01.004     Document Type: Article

References (29)

1. Turk V., Turk B., Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J 2001, 20:4629-4633.
2. Chatzizisis Y.S., Baker A.B., Sukhova G.K., et al. Augmented expression and activity of extracellular matrix-degrading enzymes in regions of low endothelial shear stress colocalize with coronary atheromata with thin fibrous caps in pigs. Circulation 2009, 123:621-630.
3. Cheng X.W., Kuzuya M., Sasaki T., et al. Increased expression of elastolytic cysteine proteases, cathepsins S and K, in the neointima of balloon-injured rat carotid arteries. Am J Pathol 2004, 164:243-251.
4. Cheng X.W., Shi G.P., Kuzuya M., Sasaki T., Okumura K., Murohara T. Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation 2012, 125:1551-1562.
5. Shi G.P., Chapman H.A., Bhairi S.M., DeLeeuw C., Reddy V.Y., Weiss S.J. Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2. FEBS Lett 1995, 357:129-134.
6. Sukhova G.K., Shi G.P., Simon D.I., Chapman H.A., Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998, 102:576-583.
7. Sasaki T., Kuzuya M., Nakamura K., et al. AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice. Atherosclerosis 2010, 210:430-437.
8. Cheng X.W., Huang Z., Kuzuya M., Okumura K., Murohara T. Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. Hypertension 2011, 58:978-986.
9. Barascuk N., Skjot-Arkil H., Register T.C., et al. Human macrophage foam cells degrade atherosclerotic plaques through cathepsin K mediated processes. BMC Cardiovasc Disord 2010, 10:19.
10. Platt M.O., Ankeny R.F., Shi G.P., et al. Expression of cathepsin K is regulated by shear stress in cultured endothelial cells and is increased in endothelium in human atherosclerosis. Am J Physiol Heart Circ Physiol 2007, 292:H1479-H1486.
11. Lutgens E., Lutgens S.P., Faber B.C., et al. Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation 2006, 113:98-107.
12. Liu J., Ma L., Yang J., et al. Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis 2006, 186:411-419.
13. Smith E.R., Tomlinson L.A., Ford M.L., McMahon L.P., Rajkumar C., Holt S.G. Elastin degradation is associated with progressive aortic stiffening and all-cause mortality in predialysis chronic kidney disease. Hypertension 2012, 59:973-978.
14. Thygesen K., Alpert J.S., Jaffe A.S., et al. Third universal definition of myocardial infarction. Eur Heart J 2012, 33:2551-2567.
15. Mintz G.S., Nissen S.E., Anderson W.D., et al. American college of cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American college of cardiology task force on clinical expert consensus documents. J Am Coll Cardiol 2001, 37:1478-1492.
16. Nakamura K., Sasaki T., Cheng X.W., Iguchi A., Sato K., Kuzuya M. Statin prevents plaque disruption in apoE-knockout mouse model through pleiotropic effect on acute inflammation. Atherosclerosis 2009, 206:355-361.
17. Nicholls S.J., Ballantyne C.M., Barter P.J., et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011, 365:2078-2087.
18. Cheng X.W., Murohara T., Kuzuya M., et al. Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol 2008, 173:358-369.
19. Cheng X.W., Kuzuya M., Sasaki T., et al. Inhibition of mineralocorticoid receptor is a renoprotective effect of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pitavastatin. J Hypertens 2011, 29:542-552.
20. Duivenvoorden R., de Groot E., Stroes E.S., Kastelein J.J. Surrogate markers in clinical trials-challenges and opportunities. Atherosclerosis 2009, 206:8-16.
21. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011, 17:1410-1422.
22. Hermus L., Lefrandt J.D., Tio R.A., Breek J.C., Zeebregts C.J. Carotid plaque formation and serum biomarkers. Atherosclerosis 2010, 213:21-29.
23. Drakopoulou M., Toutouzas K., Stefanadi E., Tsiamis E., Tousoulis D., Stefanadis C. Association of inflammatory markers with angiographic severity and extent of coronary artery disease. Atherosclerosis 2009, 206:335-339.
24. Geluk C.A., Post W.J., Hillege H.L., et al. C-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: data from the prospective PREVEND cohort. Atherosclerosis 2008, 196:372-382.
25. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995, 91:2844-2850.
26. Fukuda D., Shimada K., Tanaka A., et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 2006, 97:175-180.
27. Mello A.P., da Silva I.T., Abdalla D.S., Damasceno N.R. Electronegative low-density lipoprotein: origin and impact on health and disease. Atherosclerosis 2011, 215:257-265.
28. Oorni K., Sneck M., Bromme D., et al. Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro. J Biol Chem 2004, 279:34776-34784.
29. Lindstedt L., Lee M., Oorni K., Bromme D., Kovanen P.T. Cathepsins F and S block HDL3-induced cholesterol efflux from macrophage foam cells. Biochem Biophys Res Commun 2003, 312:1019-1024.